April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
23 citations
,
September 2013 in “Molecular Carcinogenesis” Increased Stat3 activity reduces hair follicle stem cells and boosts other stem/progenitor cells.
2 citations
,
April 2019 in “Journal of Investigative Dermatology” Gasdermin A3 causes hair follicle stem cells to activate too early, leading to hair loss.
8 citations
,
June 2023 in “European Journal of Endocrinology” The inhibitor affects androgen metabolism but not ovarian function.
July 2022 in “Journal of Investigative Dermatology”
223 citations
,
September 2018 in “Rheumatology” JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
1 citations
,
January 2023 in “Portuguese Journal of Dermatology and Venereology” JAK inhibitors effectively treat skin conditions and topical forms are safer.
3 citations
,
January 2023 in “American journal of physiology. Cell physiology” Inward rectifier potassium channels are important in many body functions and diseases, and could be potential drug targets.
22 citations
,
October 2001 in “Biochemical Pharmacology” GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.
August 2024 in “New Zealand Medical Student Journal” JAK inhibitors show promise for treating skin diseases effectively and safely.
June 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” Platelet-rich Plasma Gel may help treat en coup de sabre scleroderma, improving symptoms and skin quality with minimal side effects.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
12 citations
,
May 2010 in “Journal of Clinical Oncology” MK-5108 is safe and shows potential against tumors, especially alone.
7 citations
,
June 2011 in “Movement Disorders” A specific gene mutation is linked to a hereditary form of dystonia that responds well to certain medications.
7 citations
,
September 2024 in “The Journal of Dermatology” Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
15 citations
,
June 2011 in “Journal of Investigative Dermatology” Overexpressing 14-3-3σ in mice skin reduces cell growth and hair density.
June 1996 in “Journal of Dermatological Science” 3 citations
,
December 2018 in “Biomedical and pharmacology journal/Biomedical & pharmacology journal” Compound 3 protects the heart from damage by activating A1-adenosine receptors.
7 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” 34 citations
,
January 2023 in “Therapeutic Advances in Medical Oncology” Sacituzumab govitecan is effective but has side effects like hair loss and diarrhea in treating metastatic triple-negative breast cancer.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
10 citations
,
June 2024 in “American Journal of Clinical Dermatology” Hedgehog pathway inhibitors for advanced basal cell carcinoma can cause side effects, but managing them helps maintain treatment.
5 citations
,
January 2018 The conclusion is that a new test was created to find substances that affect specific ion channels, and it works well for drug discovery.
25 citations
,
February 2013 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking SCD1 in the skin with XEN103 shrinks sebaceous glands in mice.
September 2025 in “Acta Dermato Venereologica” Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
6 citations
,
January 2016 in “Open journal of regenerative medicine” Keratin treatment reduces astrocyte reactivity and inflammation.
3 citations
,
July 2023 in “Cells” MG53 helps reduce skin damage caused by nitrogen mustard.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia” 71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
8 citations
,
August 1987 in “The Journal of Dermatology” BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.